BPH Global Limited reported a $1.13 million half-year loss as it expands its Indonesian seaweed operations and moves to exit its China business. The company secured new capital and trade finance to support growth despite ongoing financial challenges.
- Half-year loss widened to $1.13 million
- Indonesian seaweed operation launched with secured sales agreements
- Decision to exit China operations underway
- Raised $1.1 million via private placements and secured US$375,000 trade finance
- Entered R&D collaboration MoU with Indonesia’s national innovation agency
Financial Performance and Operational Shift
BPH Global Limited has revealed a significant increase in its half-year loss, reporting a $1.13 million deficit for the six months ending 31 December 2025, up from $482,573 in the prior corresponding period. This widening loss reflects the company’s strategic pivot and investment in new growth areas, notably its expansion into Indonesia’s seaweed industry.
The company’s revenue for the period, generated entirely from its Indonesian seaweed operations, reached $1.38 million. This marks the first time BPH Global has recorded sales from this segment, following the acquisition and establishment of PT BPH Global Indonesia in 2025. The business secured offtake agreements that underpin these sales, signalling early commercial traction in a sector with growing global interest for bio-stimulants and nutraceuticals.
Exiting China and Capital Raising Efforts
Concurrently, BPH Global has made the strategic decision to exit its China operations, specifically its investment in Foshan Gedishi Biotechnology Co., Ltd. The company is actively negotiating the divestment of this subsidiary, reflecting a rationalisation of its geographic footprint and a focus on markets with clearer growth potential.
To support its operational expansion and manage liquidity, BPH Global raised $1.1 million through private placements during the half-year and secured a US$375,000 trade finance facility. These capital injections have been critical in funding the Indonesian seaweed business and ongoing research and development activities, including collaborations with Temasek Polytechnic and a recent Memorandum of Understanding with Indonesia’s Badan Riset dan Inovasi Nasional (BRIN) to advance Fucoidan extraction technology.
Financial Position and Going Concern Considerations
Despite these positive steps, the company’s balance sheet remains under pressure, with net liabilities of approximately $796,000 as at 31 December 2025, an improvement from $1.46 million six months earlier but still indicative of financial strain. The auditors have flagged material uncertainty regarding BPH Global’s ability to continue as a going concern, though management points to the recent capital raise and ongoing creditor support as mitigating factors.
The company’s directors continue to work on payment plans with creditors and are focused on growing the Indonesian operation to generate sustainable cash flow. The Indonesian subsidiary’s warehouse lease and operational infrastructure are now in place, supporting the company’s ambition to scale production and sales of seaweed and related bio-products.
Outlook and Strategic Focus
BPH Global’s half-year report underscores a transitional phase, moving away from legacy markets and investing in emerging bioresource sectors. The collaboration with BRIN and ongoing R&D into biohydrogen and mineral extraction from seaweed highlight a forward-looking innovation agenda. However, the company’s ability to convert these initiatives into profitable operations remains to be seen.
Investors will be watching closely how BPH Global manages its capital structure, executes the China divestment, and scales its Indonesian operations amid a competitive and evolving aquaculture and biotechnology landscape.
Bottom Line?
BPH Global’s bold pivot to Indonesia offers promise but hinges on successful capital management and operational execution.
Questions in the middle?
- Will BPH Global complete the divestment of its China subsidiary smoothly and at favourable terms?
- How quickly can the Indonesian seaweed operation scale to profitability and contribute positively to cash flow?
- What are the prospects and timelines for commercialising the Fucoidan extraction technology under the BRIN partnership?